| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 316.2MM | - |
| Operating Income | 132.9MM | -223% |
| Operating Expenses | 183.3MM | +46% |
| Net Income | 142.8MM | -249% |
| R&D | 140.1MM | +40% |
| G&A | 43.3MM | +70% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical trial authorisation (CTA) application by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency for BEAM-302, an in vivo base editor, as a potential treatment for patients with
As you might know, Beam Therapeutics Inc. ( NASDAQ:BEAM ) just kicked off its latest annual results with some very...
One thing we could say about the analysts on Beam Therapeutics Inc. ( NASDAQ:BEAM ) - they aren't optimistic, having...
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference, emerging genetic therapy approaches corporate panel discussion on Wednesday, March 6, 2024 at 12:50 p.m. ETLeerink Partners Global Biopharma Conference, fireside chat on Monday, Marc
Beam Therapeutics ( NASDAQ:BEAM ) Full Year 2023 Results Key Financial Results Revenue: US$377.7m (up by US$316.8m from...
Beam stock launched a year-high Tuesday as enthusiasm grows for its next-generation form of gene editing, a rival to CRISPR.
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. The Cambridge, Mass.-biotech company reported strong Q4 and full year 2023 results and reiterated milestones across the company's sickle cell disease and genetic disease portfolios. Check out "Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug."
BEAM's 2023 Earnings Highlight Strategic Progress and Robust Cash Position